# US 2021/0069199 A1 · Methods of treating transplant rejection

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0069199 A1
- Document ID: US20210069199A1
- Status: Published application
- Kind: A1
- Application number: 17/099,664
- Filed: 2020-11-16
- Published: 2021-03-11
- Earliest claimed: 2015-09-28
- Applicants: CTI BioPharma Corp.
- Inventors: Brian C. Betts; Xuezhong Yu; Claudio Anasetti
- Web page: https://patentgrep.com/patent/US20210069199A1

## CPC

- A61K 31/529: forming part of bridged ring systems
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K 31/5355: Non-condensed oxazines and containing further heterocyclic rings
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- A61K 2300/00: Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention provides the use of protein kinase inhibitors, in particular JAK2 inhibitors of formula (I), as set forth in the specification, in the treatment of solid organ transplant rejection and graft versus host disease (GvHD). Also provided are combination therapies for the treatment of solid organ transplant rejection and graft versus host disease.

## Claims

### Claim 1

A method of treating graft versus host disease (GvHD) in a mammal comprising administration to a mammal in need thereof of a therapeutically effective amount of a compound of Formula (I):
wherein:
R1 and R2 are H;
Z2 is —N(H)—;
Ar1 is selected from the group consisting of:
wherein R10 is methoxy or fluorine;
(ii) k is an integer selected from 0 or 1;
Ar2 is a group of the formula
wherein R11 is H or selected from the group consisting of:
L is a group of formula:
—X1—Y—X2—
wherein X1 is attached to Ar1 and X2 is attached to Ar2, and wherein X1, X2 and Y are selected such that the group L has between 5 and 15 atoms in the normal chain,
wherein X1 is selected from the group consisting of:
(a) —OCH2—
(b) —OCH2CH2—, and
(c) —CH2OCH2—;
wherein X2 is selected from the group consisting of:
(a) —CH2O—,
(b) —CH2CH2O—, and
(c) —CH2OCH2—;
Y is a group of formula —CRa═CRb—,
wherein Ra and Rb are H,
or a pharmaceutically acceptable salt or N-oxide thereof,
wherein the mammal has received or is currently receiving an allogeneic bone marrow or hematopoietic stem cell transplant.

### Claim 2 (depends on 1)

The method according to claim 1, wherein X1 is —CH2OCH2—.

### Claim 3 (depends on 1)

The method of claim 1, wherein X2 is —CH2OCH2—.

### Claim 4 (depends on 1)

The method of claim 1, wherein Y is selected from the group consisting of:

### Claim 5 (depends on 1)

The method of claim 1, wherein the compound of Formula (I) is selected from the group consisting of:
and pharmaceutically acceptable salts thereof.

### Claim 6 (depends on 1)

The method of claim 1, wherein the compound of Formula (I) has the following formula:
or a pharmaceutically acceptable salt thereof.

### Claim 7 (depends on 1)

The method of claim 1, wherein the compound of Formula (I) is administered concurrently with the allogeneic bone marrow or hematopoietic stem cell transplant.

### Claim 8 (depends on 1)

The method of claim 1, wherein the compound of Formula (I) is administered at a dosage of between about 0.1 mg/kg per day to about 1000 mg/kg per day.

### Claim 9 (depends on 8)

The method of claim 8, wherein the amount of the compound of Formula (I) is about 100 mg/kg per day.

### Claim 10 (depends on 1)

The method of claim 1, wherein the compound of Formula (I) is administered orally.

### Claim 11 (depends on 1)

The method of claim 1, wherein the compound of Formula (I) is administered twice per day.

### Claim 12 (depends on 1)

The method of claim 1, wherein the compound of Formula (I) is administered in combination with an anti-rejection agent selected from the group consisting of corticosteroids, calcineurin inhibitors, antiproliferative agents, monoclonal antibodies, and polyclonal antibodies.
